Company profile
SUTRO BIOPHARMA, INC.
NASDAQ:STROBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LUVELTAMAB TAZEVIBULIN | phase2_3 | — | 5 | completed, terminated, withdrawn |
| BEZETABART DEBOTANSINE | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05200364 | phase1 | terminated | 2022-03-22 | 2025-06-01 | Sutro Biopharma, Inc. | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer |
| NCT07227168 | phase1 | recruiting | 2025-11-07 | 2027-12-01 | Sutro Biopharma, Inc. | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer |
| NCT06679582 | phase1_2 | terminated | 2024-12-04 | 2025-06-01 | Sutro Biopharma, Inc. | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML |
| NCT07807345 | phase1 | not_yet_recruiting | 2026-09-14 | 2028-02-01 | Sutro Biopharma, Inc. | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic |
| NCT05870748 | phase2_3 | terminated | 2023-07-12 | 2025-08-26 | Sutro Biopharma, Inc. | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 |
FDA applications (0)
No records yet.